Asthma: Dupilumab

(asked on 18th May 2021) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of the decision by the National Institute for Health and Clinical Excellence not to recommend dupilumab for the treatment of severe asthma with Type 2 inflammation in their appraisal constitution document; and what assessment they have made of its recent approval by the Scottish Medicines Consortium for use in Scotland.


Answered by
Lord Bethell Portrait
Lord Bethell
This question was answered on 28th May 2021

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for assessing new medicines and treatments in accordance with its existing methods and processes. NICE’s draft guidance on dupilumab for consultation of 7 May 2021 states that it is not recommended for the treatment of severe asthma. NICE has not yet published its final recommendations on dupilumab and the draft guidance is now open for consultation until 28 May 2021. There will be a further meeting of NICE’s independent appraisal committee in September to consider all comments received during the consultation.

The Government has not made any assessment of the decision of the Scottish Medicines Consortium on dupilumab, as this is a devolved matter.

Reticulating Splines